intellectual property

intellectual property news

The Patent Paradox: Why India’s Startup Filing Surge is 83% Failure and All About Optics

by
Fragile gold patent scroll on a precarious foundation, with the number 83% failure rate overlaid, symbolizing the optical illusion of India's startup patent filing surge.

A deep dive into the intellectual property (IP) landscape of India’s booming startup sector reveals a critical gap between ambition and execution, suggesting that the much-lauded surge in patent filings is predominantly a tactical exercise in investor signalling rather than a genuine marker of technological innovation. The core issue, critics argue, is a “crisis of intent” where patents function as “decorative rather than functional” assets.   

While global bodies like the World Intellectual Property Organization (WIPO) have celebrated India’s rapid ascent—the WIPO 2024 report noted a phenomenal 15.7% growth in patent applications in 2023, positioning the country 6th globally with 64,480 filings —the internal data paints a sobering picture of weak follow-through.   

The Data Gap: 83% of Startup Patents Fail to Secure a Grant

Analysis of the startup patent pipeline from 2021 through 2025 reveals a profound drop-off rate, demonstrating that the vast majority of filings are not carried through to completion.   

During this five-year period, Indian startups filed a robust 13,089 patent applications. Yet, only 2,174 of these successfully navigated the examination process to achieve the grant stage. This results in a grant success rate of barely 16.6%, meaning approximately one out of every six startup filings becomes an enforceable, proprietary asset.   

The failure rate is compounded by active abandonment. Nearly 500 startup patent applications were explicitly withdrawn or abandoned early, often due to the filers failing to complete detailed specifications or respond to subsequent office actions required by the Patent Office.   

This pattern extends beyond patents. Startups filed 44,517 trademark applications during the same period, with over 1,300 subsequently abandoned. Analysts suggest this widespread non-prosecution across IP types confirms that the primary function of the filing is “brand optics” rather than a rigorous, long-term IP strategy. The high volume of dropped applications confirms that for many, the intent was temporary and instrumental: the patent filing was merely a transaction used to secure funding, not an investment in an enduring intellectual asset.   

Investor Mandate: Patents as Pitch Deck Tools

The distortion in filing behaviour is traced back to the venture capital (VC) ecosystem’s preference for strong valuation narratives. In competitive fundraising rounds, a pending patent application, particularly a cheap and fast provisional filing, serves as a high-visibility proxy for technological differentiation and market moat potential.   

A provisional patent application, which secures an immediate priority date, is leveraged as a “fast, affordable way to strengthen a fundraising narrative” and “create the appearance of a breakthrough innovation”. This mechanism enables a “Capital first, commitment later” ethos.   

The systemic issue is rooted in the fact that investors often prioritize the inclusion of an IP slide over demanding proof of prosecution commitment or demonstrated R&D investment. As the analysis notes, “Once the funding round closes, priorities may shift,” leading to a predictable loss of enthusiasm for the labour-intensive and expensive work required to turn provisional filings into complete specifications. This rational response by founders—underinvesting in expensive, long-term R&D in favour of cheap, high-volume filing tactics—systematically shifts resources away from core innovation.   

Structural Deficiency: India’s R&D Investment Stagnation

The crisis of intent at the startup level is underpinned by a deep, structural R&D deficit at the national level. The commitment to deep, foundational research necessary to generate truly novel and patentable inventions remains structurally low in India.   

Official data from the Department of Science & Technology (DST) confirms that India’s Gross Expenditure on Research and Development (GERD) as a percentage of GDP stood at 0.64% during the fiscal year 2020–21, having remained stagnant between 0.6% and 0.7% in the preceding years (0.66% in 2018–19 and 2019–20).   

This figure is significantly “below global average and lower than countries like China, South Korea and US”. This structural weakness is compounded by low private sector contribution, which accounted for only 36.4% of the total GERD in 2020–21, in sharp contrast to innovation-leading nations where private industry drives over 70% of R&D expenditure.   

This macro-level underinvestment directly correlates with the micro-level deficiencies, as most startups lack “dedicated research teams, technical drafting expertise, prior-art assessment systems, and time for iterative processes” necessary for rigorous patent prosecution.   

Policy Flaw: Incentives Reward Filing, Not Granting

Current government policies designed to stimulate IP activity, while successful in boosting filing volume, have inadvertently intensified the focus on volume over quality. The government successfully implemented significant fee concessions, including an 80% reduction in patent filing fees for startups, MSMEs, and educational institutions.   

However, the design flaw is that these incentives are tied to the input stage (filing) rather than the output stage (grant or commercialization). By heavily subsidizing the initial filing, the state inadvertently subsidizes the creation of the fundraising narrative for VCs. Once the provisional application is lodged, the startup has secured its priority date and the narrative benefit, but the subsequent costly work of prosecution remains unassisted, cementing the low-commitment behaviour.   

Blueprint for Genuine Innovation: Shifting from Decoration to Depth

To foster genuine innovation and correct the systemic inefficiencies, experts advocate for a strategic overhaul of incentives and infrastructure.   

  • Realign Incentives: Government benefits, including subsidies and fast-track examination provisions, must be decoupled from the act of filing and strategically tied to demonstrable outcomes, such as patent grants, successful long-term renewal, or demonstrable commercial utilization.   
  • Enhance Capacity: Urgent investment in the Patent Office is mandatory, including expansion of examiner capacity and specialized domain expertise. There is a pronounced need for more technically specialized patent officers, particularly in cutting-edge technological areas like AI, biotech, semiconductors, climate-tech, and advanced manufacturing.   
  • Strengthen R&D Culture: The government should offer targeted, co-funded grants and innovation-linked incentives for startups that demonstrate a commitment to establishing and maintaining dedicated R&D teams or formalized collaboration with research institutions.   
  • Promote Co-patenting: Actively promoting policy frameworks that encourage joint patent filings (co-patenting) between startups and premier academic/research institutions, such as the IITs and national labs, would guarantee a higher technical standard for the filings and create structured pathways for knowledge transfer.   

The conclusion remains clear: for India to genuinely transition from an IP volume leader to a global innovation power, the focus must shift from decorative filings to functional intellectual assets. Only then can “depth replace decoration” and solidify India’s reputation as a serious, quality-driven innovation hub.   

Fitterfly Patent Victory: AI-Driven PGR Tech Secures IP, Revolutionizes Diabetes Care in India

by
Fitterfly PGR technology patent diagram showing AI analysis of CGM data for diabetes outcomes

Digital health just scored a decisive victory. Fitterfly, the pioneering digital therapeutics arm of PB Health, secured a crucial Government of India patent. This patent protects its proprietary Personalised Glycemic Response (PGR) technology. The move cements Fitterfly’s dominant position. It dramatically alters the future of chronic disease management in India.

AI Engine Powers Precision Care

The patent covers the core of Fitterfly’s diabetes program. This AI-led engine is the PGR technology. It allows data-driven care at massive scale. PGR helps millions manage diabetes better. It predicts how specific foods and activities impact blood sugar. It makes this prediction up to three hours in advance.

This prediction power is a game-changer. It removes the daily burden of food decisions for patients. PGR moves far beyond standard, generic advice.

The model boasts a huge training dataset. It analysed over 10 lakh (1 million) Continuous Glucose Monitoring (CGM) data points. It studied over 1.21 lakh individual meals. The algorithm factors in every critical metric. These include age, BMI, heart rate, sleep, and co-morbidities. This process delivers highly accurate, personalised glucose predictions.

Clinical Outcomes Prove Efficacy

The technology already boasts unmistakable clinical success. Over 40,000 members have benefited from the PGR-powered programs. The results are clinically significant, matching high-grade pharmaceutical interventions.

In 2025, 94% of members with very high baseline HbA1c levels (above 9%) saw massive improvement. They recorded an average reduction of 2.8 points within 6 to 12 months. This outcome is comparable to standard multi-drug regimens.

Furthermore, Fitterfly’s data confirms that diabetes remission is possible. It applies to a large number of Type 2 Diabetes cases, particularly in the early stages. The program also delivers holistic health gains. Members improved critical markers. These include reduced serum cholesterol, lower triglycerides, and better blood pressure control. This success transforms patients’ quality of life. It substantially reduces future complication risks.

Dr. Vineet Nair, Head of Program Design at Fitterfly, affirmed the approach. “PGR helps us go beyond standard protocols,” he said. “It delivers care that adapts to each member’s data. This drives better adherence. It guarantees improved glucose control and more consistent progress.”

Patent Builds a Commercial Fortress

The patent acquisition is a legal triumph. It gives Fitterfly a formidable fortress of Intellectual Property (IP).

The Government of India approval confirms the unique nature of the PGR algorithm. It grants Fitterfly exclusive commercial rights. This protection shields the company from direct competition. It also exponentially increases PB Health’s valuation. The technology shifts from a service model to a protected, scalable asset.

Dr. Arbinder Singal, Head of Preventive and Digital Health at PB Health and Co-founder at Fitterfly, emphasized the strategic importance. “Our proven outcomes and proprietary technology add significant value,” he stated. “The patent secures the technical core of our chronic disease management offering.”

The move reinforces PB Health’s vision. They aim to create a tech-first, integrated healthcare ecosystem. Fitterfly’s digital expertise becomes the crucial preventative arm. This balances PB Health’s growing hospital network in the Delhi-NCR region.

India’s Health System Faces Transformation

Chronic conditions devastate India’s population. Nearly 40 percent of Indian adults suffer from diabetes, hypertension, or obesity. This is an immense, growing crisis.

Technology like PGR offers the only viable path to scale positive change. It empowers patients, doctors, and insurers alike.

For Insurers: Diabetes remains the biggest cost driver. Fitterfly’s outcome-led programs offer a clear solution. They reduce the risk of progression and expensive hospitalizations. Several leading insurance companies already recognize this shift. They integrate Fitterfly’s programs into their policyholder ecosystem. This acts as a proactive risk management measure. It lowers long-term claims.

For Patients: PGR grants control. It is a fundamental shift from reactive treatment. It establishes continuous, outcome-led management. This approach improves long-term disease stability. It leads to huge cost savings and boosts work productivity.

Dr. Singal added, “We are working closely with leading insurers. We are shifting the focus from treatment to long-term health stability. This is a crucial step. It builds a more sustainable, future-ready healthcare model for India.”

The successful patenting of PGR technology marks a definitive moment. It confirms that Digital Therapeutics (DTx) is not a supplement. DTx is becoming the first line of defence against India’s escalating chronic disease epidemic. This victory is a resounding signal. Personalised, AI-driven healthcare is now locked in. It is set to dominate the market.

Samsung Display, BOE Finalize Peace Deal in OLED Patent Battle

by

Samsung Display and BOE have officially ended their long-running dispute over OLED technology. Both companies confirmed a settlement that includes a royalty-payment agreement. The deal closes multiple lawsuits filed across the United States, China, and other markets.

Samsung Display accused BOE of infringing patents related to OLED structures and manufacturing processes. The company also alleged that BOE misused trade secrets connected to advanced display engineering. These claims triggered a series of investigations by the U.S. International Trade Commission (ITC).

The ITC ruled in March 2025 that BOE had violated three of Samsung’s OLED patents. The commission, however, stopped short of banning BOE’s OLED panel imports. Despite that, a separate ITC probe on trade secrets posed the risk of a long-term import restriction on BOE.

Both companies opted for a negotiated settlement before the trade secret ruling reached its final stage. The agreement requires BOE to license Samsung’s OLED technology. Industry analysts say this deal helps BOE protect its global shipments and maintain its presence in key smartphone and electronics markets.

For Samsung Display, the settlement reinforces the strength of its intellectual property portfolio. It also secures recurring revenue through licensing fees, strengthening its leadership in OLED innovation.

Experts believe the agreement will stabilize the OLED ecosystem. Smartphone manufacturers and device makers that rely on BOE panels are expected to benefit from the renewed supply certainty.

The settlement marks one of the most significant truces in the display industry in recent years. It also signals a shift toward licensing-driven cooperation rather than extended courtroom battles in the highly competitive display technology sector.

Supreme Court Transfers Eureka Forbes–Atomberg Patent Case to Bombay High Court

by

The Supreme Court of India has ordered the transfer of the ongoing patent infringement dispute between Eureka Forbes Limited and Atomberg Technologies Private Limited from the Delhi High Court to the Bombay High Court. The apex court took this step to prevent duplication of proceedings and avoid conflicting judgments on overlapping issues.

A bench comprising Justice Pamidighantam Sri Narasimha and Justice Atul S. Chandurkar delivered the ruling. The court found that both companies had initiated separate but related legal actions concerning the same patented technology used in Atomberg’s “Intellon” water purifier.

Background of the Dispute

Atomberg launched its Intellon water purifier on June 20, 2025. Soon after, the company filed a suit in the Bombay High Court on July 1, 2025, under Section 106 of the Patents Act, 1970, alleging groundless threats of patent infringement from Eureka Forbes.

Eureka Forbes responded by filing a patent infringement suit in the Delhi High Court on July 7, 2025, invoking Section 104 of the Patents Act. The company claimed Atomberg had violated its patent rights related to water purification technology.

The key issue was jurisdiction. Eureka Forbes argued that Delhi had jurisdiction because an online purchase and delivery of Atomberg’s product took place there. Atomberg countered that both companies’ registered offices were in Mumbai, and that the Bombay High Court was already hearing its first-filed suit on the same matter.

Supreme Court’s Findings

The Supreme Court agreed with Atomberg’s position. It noted that although the two cases were filed under different provisions of the Patents Act, the facts, evidence, and central questions were substantially identical.

The bench emphasized that allowing the cases to continue in separate courts could lead to conflicting decisions. It ruled that the Delhi High Court’s suit should be transferred to the Bombay High Court for joint consideration.

The Court further observed that the Delhi suit’s jurisdiction was based solely on a single online transaction, while the bulk of corporate activity and the first suit were linked to Mumbai.

Court’s Direction

The Supreme Court directed that the Delhi case be transferred immediately to the Bombay High Court. It also instructed both parties to seek an early hearing on the pending injunction applications to ensure swift resolution.

With this order, Atomberg’s transfer petition was allowed, and Eureka Forbes’ counter-petition seeking to move Atomberg’s case to Delhi was dismissed.

Legal and Industry Implications

The judgment highlights the Supreme Court’s effort to promote judicial efficiency and consistency in intellectual property litigation. It reinforces that when two suits involve the same facts and parties, the first-filed suit will often determine the proper jurisdiction.

The ruling also clarifies that online sales or deliveries alone do not automatically grant jurisdiction to a particular court if the primary connection and business operations lie elsewhere.

This case will likely serve as a precedent for future patent disputes, especially in the technology and consumer electronics sectors where companies frequently operate across multiple jurisdictions.

Singapore’s AEM Faces Patent Challenge

by

Singapore-based AEM Holdings Ltd has strongly denied allegations of patent infringement filed by a U.S. semiconductor company. The complaint, lodged in the U.S. District Court for the Southern District of California, accuses AEM of infringing patents related to advanced wafer-level testing systems.

The lawsuit reportedly focuses on patents covering wafer test systems equipped with thermal control technologies. The U.S. firm alleges that AEM’s testing solutions use similar methods without authorization.

AEM dismissed the claims, describing them as baseless and lacking merit. The company stated that it operates within international intellectual property laws and owns a strong portfolio of patents supporting its innovations.

“AEM strongly denies these allegations and believes the lawsuit lacks merit. We are confident this matter will not have a material impact on our operations,” the company said in an official SGX filing.

Sharp Decline in Share Value

Following the announcement, AEM’s stock fell by 9.3% on Tuesday as investors reacted to the legal development. The decline reflected market concerns over potential litigation costs, possible injunctions, and uncertainty surrounding the dispute’s outcome.

Analysts note that patent lawsuits in the semiconductor industry can take years to resolve and often involve high legal expenses. Even if a company ultimately prevails, the process can temporarily affect investor confidence and market performance.

This legal challenge comes at a time when global semiconductor manufacturers are ramping up innovation in testing and automation systems to meet rising chip demand. Intellectual property protection has therefore become a key competitive factor for industry players.

Implications for the Semiconductor Sector

The case highlights the growing frequency of intellectual property disputes within the semiconductor sector. As companies push the boundaries of chip testing and design technology, patent overlaps and legal confrontations have become more common.

If the court rules against AEM, it may face monetary penalties, licensing obligations, or the need to redesign affected products. However, if the company successfully defends itself, it could reaffirm the strength of its technology portfolio and restore market confidence.

Industry experts often observe that such disputes eventually lead to settlements or cross-licensing arrangements, allowing both parties to move forward without long-term disruptions.

AEM’s Response and Future Outlook

AEM confirmed that it has engaged legal counsel in the United States and intends to vigorously defend its position. The company reiterated that the case would not affect its business operations or financial performance.

AEM continues to expand its global presence in semiconductor test solutions, automation systems, and equipment engineering. The firm maintains that its technologies are independently developed and compliant with all applicable IP regulations.

The coming months will be crucial as AEM presents its defense and the court reviews the claims. The outcome will likely shape how technology companies manage and safeguard intellectual property in an increasingly competitive semiconductor landscape.

Bombay High Court Restores Ban on Cognizant’s Logo Use in India

by

The Bombay High Court has reinstated an injunction that bars Cognizant Technology Solutions from using its logo in India. The decision, issued on 26 August 2025, marks a setback for the U.S.-based IT services giant as it battles an ongoing trademark dispute with Atyati Technologies Pvt. Ltd.

Division Bench Overturns Earlier Relief

A division bench led by Chief Justice Alok Aradhe and Justice Sandeep V. Marne revived a March 2024 interim injunction that had originally restrained Cognizant from displaying or using the contested logo. The bench set aside a June 2024 single-judge order which had temporarily allowed Cognizant to continue using its brand mark while the case was pending.

With the latest ruling, Cognizant must immediately stop using its logo across operations in India until the trademark infringement lawsuit reaches final resolution.

Background of the Dispute

The dispute began when Atyati Technologies, a Bengaluru-based technology solutions provider, alleged that Cognizant’s logo closely resembled its registered device mark. Atyati argued that the similarity could mislead customers and erode its brand identity.

On 19 March 2024, a single-judge bench of the Bombay High Court granted an ex-parte injunction in Atyati’s favour, stopping Cognizant from using the disputed design. However, in June 2024, the same bench withdrew the order after finding that Atyati had not disclosed certain material facts. As a result, Cognizant was allowed to resume using its logo.

The 13 June 2024 order further granted Cognizant interim relief, permitting continued use of the logo during litigation. This relief has now been nullified by the division bench.

Cognizant’s Response

In a statement following the ruling, Cognizant said it would review the court’s order and explore all available legal remedies. The company emphasized its commitment to protecting its brand reputation while ensuring compliance with Indian laws.

What Lies Ahead

The case highlights the increasing importance of trademark protection in India’s IT sector, where global corporations and domestic companies frequently clash over brand identity and intellectual property. The ban could force Cognizant to temporarily rebrand its operations in India, one of its largest markets outside the United States.

The matter will now proceed to a full hearing, where the court will decide whether Cognizant’s logo indeed infringes on Atyati’s registered mark. Until then, the restored injunction will remain in effect.

Parliamentary Panel Pushes for Patent Commercialisation Hubs in IITs

by

A Parliamentary panel has recommended the creation of Patent Commercialisation Hubs at Indian Institutes of Technology (IITs) to transform academic research into market-ready products. The proposal comes from the Parliamentary Standing Committee on Commerce in its 192nd report, highlighting the need to strengthen India’s intellectual property ecosystem.

Bridging the Innovation Gap

The committee noted that while India has seen a surge in patent filings from universities and research institutions, many innovations remain unutilised. By setting up these hubs, IITs can provide infrastructure, mentorship, and technical guidance to convert patents into viable products.

The panel also urged the government to introduce matching grants for innovators. These grants would help researchers and startups build prototypes, making their technologies attractive for industry partnerships.

Incubation and Investor Linkages

The report suggested establishing Patent-to-Product Incubation Centres at IITs. These centres would offer seed funding, lab facilities, and business mentorship. More importantly, they would connect innovators with venture capitalists and private investors, ensuring that promising technologies scale effectively.

Government’s Current Measures

The Ministry of Commerce pointed out several existing initiatives. The Indian Patent Advanced Search System (inPASS) allows stakeholders to explore patents and identify potential licensing opportunities (inPASS). Patent holders can voluntarily declare their willingness to license inventions, helping industries adopt innovative solutions.

Additionally, the government has slashed patent renewal fees by 80% for startups, MSMEs, and educational institutions. This step reduces financial pressure on smaller innovators and promotes long-term patent protection.

Why It Matters

India’s educational institutions filed over 19,000 patents in FY 2023, accounting for 23% of total filings. This marks a sharp rise from 7,200 in FY 2022. Yet, challenges such as long patent approval timelines—around 51 months—continue to hamper innovation.

The proposed hubs can bridge this gap by ensuring patents are not just filed but also commercialised. Such efforts could position India as a stronger global player in innovation.

Outlook

If implemented, these hubs could redefine India’s innovation ecosystem. IITs, with their research capabilities and industry linkages, are well-placed to lead this initiative. The move aligns with India’s ambition to strengthen its intellectual property rights (IPR) regime and drive economic growth through technology-driven enterprises.

Nike-New Balance Patent Lawsuit Paused Amid PTAB Review, Judge Rules

by

A federal judge has paused a high-stakes patent dispute between global sportswear giants Nike Inc. and New Balance Athletics, Inc., granting a temporary stay in litigation as the U.S. Patent Trial and Appeal Board (PTAB) reviews several of Nike’s Flyknit patents at the heart of the case.

On June 6, U.S. District Judge Julia E. Kobick ruled in favor of New Balance’s motion to stay the case until August 9, 2025, aligning with the expected PTAB decisions. Nike alleges that New Balance infringed on nine of its Flyknit patents across 61 different shoe models, claiming that the Boston-based company copied its innovative, lightweight knit sneaker technology.

New Balance requested the pause, citing that the PTAB is already actively reviewing six of the nine contested patents. The company argued that a stay would promote judicial efficiency and possibly narrow or eliminate the need for trial if some patents are invalidated.

Judge Kobick, in her ruling, agreed with New Balance’s position, stating that continuing the case while the PTAB deliberates could lead to duplicative proceedings. “Nike has not shown that it will suffer undue prejudice beyond the delay,” Kobick noted, indicating that a short pause would not cause significant harm to the plaintiff.

The judge also highlighted New Balance’s commitment to continue discovery during the stay, including the collection of documents and depositions from international partners. This assurance helped alleviate concerns about lost evidence or unavailable witnesses during the delay.

Nike’s Flyknit technology, first introduced in 2012, is considered a major breakthrough in performance footwear design. The company holds several patents on the material structure, stitching techniques, and manufacturing methods used to create a sock-like fit with minimal waste. Nike contends that New Balance’s knit-based designs unlawfully mirror its patented Flyknit technology.

If the PTAB invalidates some or all of the Flyknit patents under review, it could significantly alter the direction of the case, weakening Nike’s claims and reducing the number of infringing products. Conversely, if the patents are upheld, New Balance may face greater legal exposure and could be required to stop sales or negotiate licensing terms.

The litigation pause is temporary, with proceedings expected to resume following the PTAB’s decisions in August. The outcome will be closely watched by the industry, as it may set a precedent for how similar intellectual property disputes are handled between major athletic brands.

For now, both companies await the PTAB’s judgment, which could either simplify the lawsuit—or set the stage for a prolonged legal battle over innovation in athletic footwear.

Acadia Pharmaceuticals Clinches Patent Victory for NUPLAZID Composition

by

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) secured a critical legal win on Tuesday after the U.S. Court of Appeals for the Federal Circuit upheld the validity of the company’s composition of matter patent for its flagship drug, NUPLAZID (pimavanserin). The decision preserves Acadia’s exclusive rights under the ’740 patent and delivers a setback to challengers MSN Laboratories Private Ltd. and MSN Pharmaceuticals, Inc.

The court’s affirmation confirms a lower court ruling that had sided with Acadia in its patent dispute, cementing the biotech firm’s control over the proprietary formulation of NUPLAZID, a therapy approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

“This ruling reinforces the strength of our intellectual property portfolio and our commitment to defending the innovation behind NUPLAZID,” said Steve Davis, CEO of Acadia Pharmaceuticals, in a statement following the announcement. “We are pleased that the court has once again validated our patent, enabling us to continue focusing on delivering therapies to patients with unmet medical needs.”

The legal battle stemmed from efforts by MSN Laboratories and its U.S. affiliate to invalidate Acadia’s ’740 patent, which they argued was not novel or sufficiently inventive. The appellate court rejected these arguments, siding with the company and affirming the patent’s enforceability until its expiration.

The timing of the ruling coincides with Acadia’s robust financial performance. Over the last twelve months, the company has reported revenues nearing $1 billion, with a notable 60% gross margin—a figure that highlights operational efficiency and pricing power in the specialty pharmaceutical market. According to InvestingPro, Acadia currently boasts a “GREAT” financial health score, with more than ten positive metrics contributing to its investment outlook.

Legal experts suggest this ruling will deter potential generic competition in the near term, securing continued market exclusivity for Acadia and potentially preserving its revenue stream from NUPLAZID. The drug remains the first and only FDA-approved treatment for Parkinson’s disease psychosis, positioning it as a valuable asset in Acadia’s expanding neuroscience pipeline.

With the legal hurdle now cleared, analysts anticipate that Acadia will intensify its strategic investments in late-stage clinical programs and explore additional therapeutic indications for pimavanserin.

The decision not only strengthens Acadia’s intellectual property rights but also underscores the importance of robust patent protection in the competitive pharmaceutical sector, where market exclusivity often dictates the pace of innovation and return on investment.

About Acadia Pharmaceuticals:
Founded in 1993 and headquartered in San Diego, California, Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address central nervous system disorders. Its lead product, NUPLAZID, is approved in the U.S. and continues to be studied for multiple neuropsychiatric indications.

BITS Law School Launches Centre for Research on Innovation Law for Shared Prosperity (CRISP); Hosts Inaugural Innovation Law & Policy Fellowship Conference

by

In a significant step toward fostering inclusive and future-oriented legal research, BITS Law School has announced the establishment of its Centre for Research on Innovation Law for Shared Prosperity (CRISP). The announcement was made during the inaugural conference of the Innovation Law & Policy Fellowship, held at the BITS Pilani Mumbai Campus.

The launch of CRISP marks a strategic move by BITS Law School to advance interdisciplinary research at the intersection of law, innovation, and equitable development. With India emerging as a global hub for technology and innovation, CRISP aims to explore how legal frameworks can support inclusive and sustainable progress.

The inaugural conference served as both a ceremonial and scholarly beginning for the Innovation Law & Policy Fellowship program. Distinguished legal scholars, industry leaders, policymakers, and research fellows convened to deliberate on how legal systems can evolve in response to rapid technological change while ensuring societal welfare.

Driving Innovation Through Law

Speaking at the event, Founding Dean of BITS Law School, Dr. Rishad Chowdhury, emphasized the role of CRISP in bridging the gap between legal theory and real-world policy challenges. “CRISP is not just a research centre; it is a catalyst for systemic transformation. Our goal is to equip policymakers and institutions with evidence-based insights that help balance innovation with justice, equity, and prosperity for all,” he said.

The centre will prioritize research in areas such as intellectual property, digital governance, biotechnology regulation, climate change law, and access to innovation in marginalized communities. Its core objective is to promote shared prosperity by making legal innovation inclusive and accessible.

Fellowship Program to Build Legal Talent for the Future

The Innovation Law & Policy Fellowship, launched in tandem with CRISP, seeks to nurture emerging legal thinkers committed to reimagining law for the innovation economy. The competitive fellowship offers early-career scholars an opportunity to engage in rigorous research under the mentorship of senior faculty and collaborate with national and international institutions.

Keynote addresses at the conference were delivered by prominent figures in the legal and technology sectors, including Justice (Retd.) Srikrishna, known for his pioneering work in data protection law, and Dr. Arundhati Bhattacharya, Chairperson of the India Digital Innovation Council. Their talks highlighted the urgent need for agile, responsive legal frameworks in the age of AI, data, and decentralized technologies.

A Vision for Inclusive Legal Futures

Participants at the conference discussed pressing challenges such as regulatory sandboxes for startups, innovation gaps in rural India, and global frameworks for equitable technology transfer. Panel sessions featured academics from top law schools, representatives from think tanks, and innovation-focused NGOs.

The event concluded with a roadmap presentation by the CRISP leadership team, outlining upcoming research themes, collaborative projects, and policy engagement initiatives.

About BITS Law School

Established under the aegis of the prestigious Birla Institute of Technology and Science (BITS), BITS Law School is a modern, interdisciplinary institution committed to reshaping legal education and policy-making in India. With CRISP now a part of its expanding research ecosystem, the law school reinforces its mission to contribute meaningfully to society through impactful legal research and advocacy.

As India navigates complex technological and societal shifts, the creation of CRISP positions BITS Law School as a thought leader in developing a legal infrastructure that promotes both innovation and equity.